Literature DB >> 12127310

Production of a Mycobacterium avium ssp. paratuberculosis purified protein derivative (PPD) and evaluation of potency in guinea pigs.

E M Steadham1, B M Martin, C O Thoen.   

Abstract

A Mycobacterium avium ssp. paratuberculosis purified protein derivative (PPD) was produced and the biologic activity evaluated in sensitized guinea pigs. The PPD when adjusted to a protein concentration of 1mg/ml induced a delayed-type hypersensitivity response comparable to USDA Johnin OT 133-8707. Copyright 2002 The International Association for Biologicals. Published by Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12127310     DOI： 10.1006/biol.2002.0321

Source DB:  PubMed          Journal:  Biologicals        ISSN： 1045-1056            Impact factor:   1.856


  4 in total

1.  Profiling bovine antibody responses to Mycobacterium avium subsp. paratuberculosis infection by using protein arrays.

Authors:  John P Bannantine; Michael L Paustian; W Ray Waters; Judith R Stabel; Mitchell V Palmer; Lingling Li; Vivek Kapur
Journal:  Infect Immun       Date:  2007-11-26       Impact factor: 3.441

2.  Failure of antigen-stimulated gammadelta T cells and CD4+ T cells from sensitized cattle to upregulate nitric oxide and mycobactericidal activity of autologous Mycobacterium avium subsp. paratuberculosis-infected macrophages.

Authors:  Frank J Simutis; Douglas E Jones; Jesse M Hostetter
Journal:  Vet Immunol Immunopathol       Date:  2007-01-09       Impact factor: 2.046

3.  Genetic analysis of Mycobacterium avium complex strains used for producing purified protein derivatives.

Authors:  Makeda Semret; Douwe Bakker; Nonie Smart; Ingrid Olsen; Kaare Haslov; Marcel A Behr
Journal:  Clin Vaccine Immunol       Date:  2006-09

4.  Composition and Potency Characterization of Mycobacterium avium subsp. paratuberculosis Purified Protein Derivatives.

Authors:  Randal T Capsel; Charles O Thoen; Timothy A Reinhardt; John D Lippolis; Renee Olsen; Judith R Stabel; John P Bannantine
Journal:  PLoS One       Date:  2016-05-02       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.